TEVA PHARMACEUTICAL-SP ADR
TEVANYSEUS Equity
$834.13▲ $74.82 (+8.97%)
Simulated price1h—
24h▲ 9.0%
7d▲ 2303.1%
14d▲ 2302.4%
30d▲ 2490.5%
1y▲ 4923.4%
🏦Market Cap
$290.02B
Large Cap
📈Revenue Growth (YoY)
+4.1%
Slowing
📊Gross Margin
52.9%
Healthy
💵FCF Margin
9.0%
Moderate
⚖️P/S Ratio
2.4x
Cheap
Otter Score
68
Fair
Trading Snapshot
- Day Range
- $824.29 – $847.81
- 52-Week Range
- $5,434.00 – $11,350.00
- Volume
- $3.48B
- Avg Volume
- $3.45B
- Shares Outstanding
- 1.16B
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $25.89B
- Last Q Revenue
- $5.85B
- P/E Ratio
- 57.5
- P/S Ratio
- 2.4x
- EPS (TTM)
- $0.60
- Dividend Yield
- —
Why Investors Own TEVA
- ✓High-growth profile — revenue up +34.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$25.89B▲ +39.9% YoY
Gross Margin (TTM)
36.2%▲ +4.2% YoY
Operating Income (TTM)
$7.12B▲ +39.9% YoY
Free Cash Flow (TTM)
$4.56B▲ +39.9% YoY
About TEVA PHARMACEUTICAL-SP ADR
A company profile for TEVA PHARMACEUTICAL-SP ADR isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
68/100
Analyst Price Target
ⓘAverage Target
$961.38
▲ +15.3% Upside
High Target$1,191.71
Low Target$822.52
Based on 38 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
TEVA PHARMACEUTICAL-SP ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift TEVA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
TEVA PHARMACEUTICAL-SP ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.